Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is 1 of the promising stocks to bargain nether $50. On January 8, Morgan Stanley expert Maxwell Skor lowered the firm’s terms people connected Ultragenyx to $50 from $55 and kept an Overweight standing connected the shares. The steadfast projects continued outperformance for US SMID-cap biotech successful 2026. This bullish outlook is driven by commercial-stage companies transitioning from superior consumers to producers, combined with a looming patent cliff that threatens the gross of large-cap biopharma.

In different news, connected December 30, Ultragenyx Pharmaceutical completed its rolling BLA submission to the FDA for DTX401, which is simply a imaginable first-in-class cistron therapy for Glycogen Storage Disease Type Ia/GSDIa. The exertion was finalized with the submission of the manufacturing/CMC module, pursuing objective and non-clinical information filed successful August. If approved, DTX401 volition code the basal origin of this life-threatening metabolic disorder, which presently forces 6,000 patients worldwide to trust connected rigorous, 24-hour cornstarch dosing to debar fatal hypoglycemia.

The submission is backed by the Phase 3 GlucoGene study, which followed 52 patients for up to six years. Safety information done 96 weeks confirmed that DTX401 is well-tolerated. The therapy holds respective high-priority designations, including RMAT and Fast Track, arsenic it nears a imaginable commercialized motorboat to regenerate the dense dietary load of GSDIa.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is simply a biopharmaceutical institution that identifies, acquires, develops, and commercializes caller products for the attraction of uncommon and ultra-rare familial diseases successful North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.